Progress in precision therapy in pediatric oncology

被引:6
|
作者
O'Donohue, Tara [1 ]
Sait, Sameer Farouk [1 ]
Bender, Julia Glade [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pediat, Clin Res, 1275 York Ave, New York, NY 10065 USA
关键词
molecular profiling; precision oncology; targeted therapy; ADVANCED MALIGNANCIES ARMS; ACSE-ESMART; TOPOTECAN-TEMOZOLOMIDE; SOLID TUMORS; CHILDREN; TRIAL; COMBINATION; DABRAFENIB; CANCERS;
D O I
10.1097/MOP.0000000000001198
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Purpose of reviewThe fields of precision medicine and cancer genomics in pediatric oncology are rapidly evolving. Novel diagnostic tools are critical in refining cancer diagnoses, stratifying patient risk, and informing treatment decisions. This review is timely and relevant as it discusses advantages and drawbacks of common molecular profiling techniques and highlights novel platforms, which may address select limitations. We discuss recent publications demonstrating utility of large-scale molecular profiling and feasibility and logistics of matching targeted therapies to patients.Recent findingsWe describe the increased accessibility of next-generation sequencing, complementary profiling methods, and strategies to guide treatment decisions. We describe curation and sharing of large genomic datasets and novel mechanisms to obtain matched targeted therapies. Importantly, we discuss relevant publications in distinct disease domains that support indications for evidence-based precision therapy. Lastly, we introduce the incremental analyses that can be obtained via whole-genome and transcriptome sequencing.Here we highlight high-yield clinical scenarios of precision medicine approaches and identify the ongoing challenges including universally defining clinical actionability, optimizing trial design to account for molecular heterogeneity while acknowledging limitations in patient accrual, expanding access to molecularly targeted therapies, and validating new tools and technology to aid in precision medicine therapeutic approaches.
引用
收藏
页码:41 / 47
页数:7
相关论文
共 50 条
  • [31] Exploring Play Therapy in Pediatric Oncology: A Preliminary Endeavour
    Chari, Uttara
    Hirisave, Uma
    Appaji, L.
    INDIAN JOURNAL OF PEDIATRICS, 2013, 80 (04) : 303 - 308
  • [32] Precision Oncology in Hepatopancreatobiliary Cancer Surgery
    Newhook, Timothy E.
    Tsai, Susan
    Meric-Bernstam, Funda
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 33 (02) : 343 - 367
  • [33] Precision oncology: East meets West
    Subbiah, Vivek
    Rodon, Jordi
    Yap, Timothy A.
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (09) : 1734 - 1737
  • [34] Top advances of the year: Precision oncology
    Desai, Aakash
    Reddy, Neha K.
    Subbiah, Vivek
    CANCER, 2023, 129 (11) : 1634 - 1642
  • [35] Molecular and modular intricacies of precision oncology
    Chhabra, Ravneet
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [36] The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead
    Evans, William E.
    Pui, Ching-Hon
    Yang, Jun J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (01) : 176 - 180
  • [37] A Review of Precision Oncology Knowledgebases for Determining the Clinical Actionability of Genetic Variants
    Li, Xuanyi
    Warner, Jeremy L.
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [38] Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology
    Capuozzo, Maurizio
    Santorsola, Mariachiara
    Landi, Loris
    Granata, Vincenza
    Perri, Francesco
    Celotto, Venere
    Gualillo, Oreste
    Nasti, Guglielmo
    Ottaiano, Alessandro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [39] The molecular tumor board: a tool for the governance of precision oncology in the real world
    Incorvaia, Lorena
    Russo, Antonio
    Cinieri, Saverio
    TUMORI JOURNAL, 2022, 108 (04): : 288 - 290
  • [40] The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
    van Tilburg, Cornelis M.
    Pfaff, Elke
    Pajtler, Kristian W.
    Langenberg, Karin P. S.
    Fiesel, Petra
    Jones, Barbara C.
    Balasubramanian, Gnana Prakash
    Stark, Sebastian
    Johann, Pascal D.
    Blattner-Johnson, Mirjam
    Schramm, Kathrin
    Dikow, Nicola
    Hirsch, Steffen
    Sutter, Christian
    Grund, Kerstin
    von Stackelberg, Arend
    Kulozik, Andreas E.
    Lissat, Andrej
    Borkhardt, Arndt
    Meisel, Roland
    Reinhardt, Dirk
    Klusmann, Jan-Henning
    Fleischhack, Gudrun
    Tippelt, Stephan
    von Schweinitz, Dietrich
    Schmid, Irene
    Kramm, Christof M.
    von Bueren, Andre O.
    Calaminus, Gabriele
    Vorwerk, Peter
    Graf, Norbert
    Westermann, Frank
    Fischer, Matthias
    Eggert, Angelika
    Burkhardt, Birgit
    Woessmann, Wilhelm
    Nathrath, Michaela
    Hecker-Nolting, Stefanie
    Fruehwald, Michael C.
    Schneider, Dominik T.
    Brecht, Ines B.
    Ketteler, Petra
    Fulda, Simone
    Koscielniak, Ewa
    Meister, Michael T.
    Scheer, Monika
    Hettmer, Simone
    Schwab, Matthias
    Tremmel, Roman
    Ora, Ingrid
    CANCER DISCOVERY, 2021, 11 (11) : 2764 - 2779